Cti Biopharma Corp
CTICDelisted Jun 26, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000891293
Cti Biopharma Corp was delisted on Jun 26, 2023; its insiders filed their last Form 4 on Jun 28, 2023; 133 institutions reported holding it in 13F filings for Q1 2023, worth $475.2M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 133
- Q1 2023, −12 vs. previous quarter
- 13F value
- $475.2M
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding CTIC, Q1 2023
No superinvestor reported holding CTIC at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by Cti Biopharma Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 26, 2023 (view filing) | Jan 24 | 2 days | Craig Adam RPresident and CEO | SSale | −85.3K | $6.00 | −$511.9K | −74.3%29.4K after | 2 lots |
| Jan 26, 2023 (view filing) | Jan 24 | 2 days | Fong James KEVP & Chief Commercial Officer | SSale | −100.0K | $6.00 | −$600.0K | −96.6%3.56K after | |
| Jan 3, 2023 (view filing) | Dec 29, 2022-Jan 3, 2023 | 5 days | Craig Adam RPresident and CEO | SSale | −115.6K | $6.01 | −$694.4K | −79.7%29.4K after | 5 lots |
| Jan 3, 2023 (view filing) | Dec 29, 2022-Jan 3, 2023 | 5 days | Kirske DavidEVP, Chief Financial Officer | SSale | −54.0K | $6.01 | −$324.5K | −75.9%17.1K after | 5 lots |
| Nov 14, 2022 (view filing) | Nov 9-10 | 5 days | Craig Adam RPresident and CEO | SSale | −242.3K | $6.00 | −$1.45M | −89.7%27.9K after | 10 lots |
| Nov 10, 2022 (view filing) | Nov 8 | 2 days | Metzger Michael ADirector | SSale | −91.5K | $5.59 | −$511.2K | −100.0%0 after | 3 lots |
| Oct 6, 2022 (view filing) | Oct 4 | 2 days | Kirske DavidEVP, Chief Financial Officer | SSale | −2.11K | $6.26 | −$13.2K | −11.1%16.9K after | 3 lots |
| Oct 3, 2022 (view filing) | Sep 29-Oct 3 | 4 days | Kirske DavidEVP, Chief Financial Officer | SSale | −141.0K | $6.05 | −$853.3K | −89.3%16.9K after | 4 lots |
| Sep 20, 2022 (view filing) | Sep 16 | 4 days | Kirske DavidEVP, Chief Financial Officer | SSale | −22.6K | $6.02 | −$136.0K | −57.2%16.9K after | |
| Sep 14, 2022 (view filing) | Sep 12 | 2 days | Craig Adam RPresident and CEO | SSale | −242.3K | $6.43 | −$1.56M | −89.7%27.9K after |
Top 10 13F holders, Q1 2023
The largest institutional positions in Cti Biopharma Corp at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| State Street Corp | 12,437,278 | $52.2M | 0.00% | −3,565,711−22.3% | Reduced |
| Rubric Capital Management LP | 8,963,256 | $37.6M | 1.50% | +8,963,256 | New |
| BVF Inc | 8,813,021 | $37.0M | 1.35% | 00.0% | Unchanged |
| BlackRock Inc. | 7,102,626 | $29.8M | 0.00% | +42,307+0.6% | Added |
| Stonepine Capital Management, LLC | 6,535,674 | $27.4M | 9.21% | +1,601,574+32.5% | Added |
| Marshall Wace, LLP | 5,960,103 | $25.0M | 0.06% | +5,960,103 | New |
| Vanguard Group Inc | 5,957,730 | $25.0M | 0.00% | +386,319+6.9% | Added |
| Bain Capital Life Sciences Investors, LLC | 4,702,996 | $19.8M | 2.47% | +925,688+24.5% | Added |
| Bleichroeder LP | 3,893,730 | $16.4M | 3.49% | 00.0% | Unchanged |
| NEA Management Company, LLC | 3,685,683 | $15.5M | 1.07% | 00.0% | Unchanged |